Navigation Links
Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
Date:3/11/2008

LAS VEGAS, March 11 /PRNewswire/ -- Altogen Biosystems (http://www.altogen.com) announced launch of new contract research services. Located in Las Vegas, NV, Altogen Custom Services focus on providing specialized biotechnology and pharmaceutical services, including RNA Interference (RNAi) services, generation of stably-expressing cell lines, assay development, screening and transfection services. In particular, the company will draw upon their unique experience with over hundred cancer cell lines and expertise in polymer and nanoparticle-based gene delivery technologies.

Generation of stably-expressing cancer cell lines and primary cells can be very expensive and time-consuming. Utilizing this method, investigators are able to develop cells that permanently express specific genes through their incorporation in the cellular genome. Altogen Custom Services offers generation of stable cell lines by transforming the cell line of choice to stably express vector or gene of interest. Optional cloning and shRNA expression services are available. The service turnaround time is typically 3-4 weeks.

Altogen laboratory research services (http://www.altogen.com/support.htm) include:

-- Transfection services (transient and stable)

-- Assay development and library screening

-- Cloning and plasmid vector construction

-- Generation of stable cell lines

-- RNAi experiments (siRNA design, synthesis, validation)

-- Gene targeting (mRNA knockdown, shRNA overexpression)

-- Custom services

About Altogen Biosystems

Altogen Biosystems is a life sciences company dedicated to the development, marketing and manufacture of In Vivo and In Vitro transfection reagents for intracellular and tissue-targeted delivery of biomolecules. Altogen Custom Services is a laboratory contract research organization.
'/>"/>

SOURCE Altogen Biosystems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
2. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
3. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
4. Primera Biosystems Raises $21 Million in Series B Private Round
5. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Moleac Launches NeuroAid10(TM) in the United States
8. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
9. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
10. BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services
11. ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... Research and Markets  has announced the ... by Application, Geography - Global Analysis and Forecast (2014 ... Organic electronics, also called as polymer electronics or ... deals with small conductive molecules and electrically conductive polymers. ... polymers are carbon based, made using synthetic strategies developed ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... 23, 2012 SiREM ( www.siremlab.com ) and ... signing of a Sales Agency Agreement between the ... Tersus Environmental will market, promote and sell SiREM,s ... as well as Gene-Trac® molecular testing services and ...
... Mich. and AMSTERDAM, Feb. 23, 2012   Rubicon ... sample-specific pre-analytical processes to improve the capabilities ... platforms, today announced a clinical supply agreement ... TransPLEX® whole genome RNA amplification technology.  Agendia ...
... Inc. (OTCBB: AMBS), a biotechnology company developing MANF, ... Gerald E. Commissiong, President and CEO, will present ... National Investment Banking Association (NIBA) conference on Thursday, ... Pavillon Hotel in New Orleans, LA. Mr. Commissiong ...
Cached Biology Technology:Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 3Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans 2
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
(Date:10/15/2014)... resistance to bacterial pneumonia in female mice to an ... Females are naturally more resistant to respiratory infections than ... that increased resistance to bacterial pneumonia in female mice ... (NOS3). They also show that this enzyme is ultimately ... estrogen. , The team, lead by Professor Lester Kobzik ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... Researchers at St. Michael,s Hospital have put forward a ... condition that occurs when infection spreads throughout the body. ... rather than a symptom as previously thought, said Dr. Warren ... research on sepsis were published today in the journal ...
... (Bethesda, MD): Today, on behalf of the Association for ... at the US Food and Drug Administration,s (FDA) meeting ... Approaches to Assess Analytical Validity." As they begin ... advised FDA officials on many important considerations for evaluating ...
... huge expanses of the North Pacific Ocean are major corridors ... seasonal patterns, according to final results from the Census of ... today in the journal Nature ., The paper culminates ... movements in the Pacific Ocean. It presents for the first ...
Cached Biology News:Researchers suggest new way of looking at what causes sepsis 2AMP comments at FDA meeting on next-generation sequencing 2Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 2Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 3Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 4Teeming with life, Pacific's California current likened to Africa's Serengeti Plain 5
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
Request Info...
... materials necessary for the isolation and preparation of ... Kit Components: Erythrocyte ... containing 220 mL of buffered ammonium chloride. (NH ... No. 5113) One bottle containing 220 mL of ...
... For use with suspension (non-adherent) ... uses vacuum filtration or centrifugation ... media. Compatible with 96-well ... in larger package sizes and ...
Biology Products: